Laura L Stafman1, Mary G Waldrop1, Adele P Williams1, Jamie M Aye2, Jerry E Stewart1, Elizabeth Mroczek-Musulman3, Karina J Yoon4, Kimberly Whelan2, Elizabeth A Beierle5. 1. Department of Surgery, University of Alabama at Birmingham, Birmingham, AL. 2. Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL. 3. Department of Pathology, Children's of Alabama, Birmingham, AL. 4. Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL. 5. Department of Surgery, University of Alabama at Birmingham, Birmingham, AL. Electronic address: elizabeth.beierle@childrensal.org.
Abstract
PURPOSE: Hepatoblastoma is the most common primary liver cancer of childhood and has few prognostic indicators. We have previously shown that Proviral Integration site for Moloney murine leukemia virus (PIM3) kinase decreased hepatoblastoma tumorigenicity. We sought to determine the effect of PIM3 overexpression on hepatoblastoma cells and whether expression of PIM3 correlated with patient/tumor characteristics or survival. METHODS: The hepatoblastoma cell line, HuH6, and patient-derived xenograft, COA67, were utilized. Viability, proliferation, migration, sphere formation, and tumor growth in mice were assessed in PIM3-overexpressing cells. Immunohistochemistry was performed for PIM3 on patient samples. Correlation between stain score and clinical/pathologic characteristics was assessed. RESULTS: PIM3 overexpression rescued the anti-proliferative effect observed with PIM3 knockdown. Sphere formation was increased in PIM3 overexpressing cells. Cells with PIM3 overexpression yielded larger tumors than those with empty vector. Seventy-four percent of samples expressed PIM3. There was no statistical difference in patient characteristics between subjects with strong versus weak PIM3 staining, but patients with strong PIM3 staining had decreased survival. CONCLUSIONS: PIM3 expression plays a role in hepatoblastoma tumorigenesis. PIM3 was present in the majority of hepatoblastomas and higher PIM3 expression correlated with decreased survival. PIM3 warrants investigation as a therapeutic target and prognostic marker for hepatoblastoma.
PURPOSE:Hepatoblastoma is the most common primary liver cancer of childhood and has few prognostic indicators. We have previously shown that Proviral Integration site for Moloney murine leukemia virus (PIM3) kinase decreased hepatoblastoma tumorigenicity. We sought to determine the effect of PIM3 overexpression on hepatoblastoma cells and whether expression of PIM3 correlated with patient/tumor characteristics or survival. METHODS: The hepatoblastoma cell line, HuH6, and patient-derived xenograft, COA67, were utilized. Viability, proliferation, migration, sphere formation, and tumor growth in mice were assessed in PIM3-overexpressing cells. Immunohistochemistry was performed for PIM3 on patient samples. Correlation between stain score and clinical/pathologic characteristics was assessed. RESULTS:PIM3 overexpression rescued the anti-proliferative effect observed with PIM3 knockdown. Sphere formation was increased in PIM3 overexpressing cells. Cells with PIM3 overexpression yielded larger tumors than those with empty vector. Seventy-four percent of samples expressed PIM3. There was no statistical difference in patient characteristics between subjects with strong versus weak PIM3 staining, but patients with strong PIM3 staining had decreased survival. CONCLUSIONS:PIM3 expression plays a role in hepatoblastoma tumorigenesis. PIM3 was present in the majority of hepatoblastomas and higher PIM3 expression correlated with decreased survival. PIM3 warrants investigation as a therapeutic target and prognostic marker for hepatoblastoma.
Authors: Teija L T Aho; Jouko Sandholm; Katriina J Peltola; Harri P Mankonen; Michael Lilly; Päivi J Koskinen Journal: FEBS Lett Date: 2004-07-30 Impact factor: 4.124
Authors: Maretta De Ioris; Laurence Brugieres; Arthur Zimmermann; Jean Keeling; Penelope Brock; Rudolf Maibach; Jon Pritchard; Liz Shafford; Joszef Zsiros; Piotr Czaudzerna; Giorgio Perilongo Journal: Eur J Cancer Date: 2007-12-31 Impact factor: 9.162
Authors: Fang Cheng; Magdalena Weidner-Glunde; Markku Varjosalo; Eeva-Marja Rainio; Anne Lehtonen; Thomas F Schulz; Päivi J Koskinen; Jussi Taipale; Päivi M Ojala Journal: PLoS Pathog Date: 2009-03-06 Impact factor: 6.823
Authors: Nikita Wadhwani; Hooper R Markert; Raoud Marayati; Laura V Bownes; Colin H Quinn; Jamie M Aye; Jerry E Stewart; Karina J Yoon; Elizabeth A Beierle Journal: J Pediatr Surg Date: 2021-02-24 Impact factor: 2.549
Authors: Laura L Stafman; Adele P Williams; Raoud Marayati; Jamie M Aye; Hooper R Markert; Evan F Garner; Colin H Quinn; Shoeb B Lallani; Jerry E Stewart; Karina J Yoon; Kimberly Whelan; Elizabeth A Beierle Journal: Sci Rep Date: 2019-09-13 Impact factor: 4.379
Authors: Raoud Marayati; Laura L Stafman; Adele P Williams; Laura V Bownes; Colin H Quinn; Hooper R Markert; Juliet L Easlick; Jerry E Stewart; David K Crossman; Elizabeth Mroczek-Musulman; Elizabeth A Beierle Journal: Cancer Gene Ther Date: 2021-04-16 Impact factor: 5.854
Authors: Raoud Marayati; Laura L Stafman; Adele P Williams; Laura V Bownes; Colin H Quinn; Jamie M Aye; Jerry E Stewart; Karina J Yoon; Joshua C Anderson; Christopher D Willey; Elizabeth A Beierle Journal: Sci Rep Date: 2021-03-16 Impact factor: 4.379